- Sexualite
- Published:
Androgènes et sexualité masculine
Androgens and male sexuality
Andrologie volume 6, pages 387–397 (1996)
Resume
La testostérone (T) est indispensable au maintien de la fonction sexuelle chez l'homme. Elle agit sur toutes les composantes de l'acte sexuel: libido, érection et éjaculation. Au niveau de l'érection, seules les érections spontanées nocturnes sont androgénodépendantes à l'inverse de celles provoquées par fantasmes ou par stimulation visuelle.
C'est essentiellement sous forme de dihydrotestostérone (DHT) que l'hormone mâle semble exercer ses actions aussi bien au niveau central que périphérique. Une intervention au niveau cérébral des estrogènes (E) produits localement ne peut cependant pas être formellement écartée.
Les concentrations de T requises pour le rétablissement de la fonction sexuelle en cas d'hypogonadisme sont proches de la limite inférieure des valeurs normales. le seuil supérieur d'action de la T sur la sexualité-s'il existe- se situerait à des niveaux supraphysiologiques.
L'androgénothérapie des dysfonctionnements sexuels est en pleine évolution. De nouveaux produits plus performants et de nouvelles voies d'administration moins astreignantes et plus physiologiques sont en cours d'évaluation. De plus l'affinement de l'exploration des androgènes plasmatiques associé à une meilleure compréhension des effets secondaires de la thérapeutique androgénique laissent espérer l'obtention dans un proche avenir d'un consensus autour de l'élargissement du champ d'indications de l'androgénothérapie.
Abstract
Testosteron is known to be critical for the right maintenance of masculin sexuality. It acts on all components of sexuality: libido, erection and ejaculation. As far as erection is concerned, one has to emphasize on the fact that only spontaneous nocturnal erections are androgen-dependent unlike erectile responses to visual erotic stimuli
The T can act, at the level of target organes, either as unchanged or as more often observed after reduction to DHT or aromatisation to E2. It is essencially as DHT that the male hormone seems to act on the sexuality at both the central and peripherical levels. The oestrogens even if now shown to have no peripherical action, are still subject to controversy as far as their central action is concerned. Therefore an action at the cerebral level of the oestrogens produced locally can not be definitively eliminated.
The concentrations of T required for the re-establishment of the sexual function in case of hypogonadism are closer to the lower limits of normal values. The upper treshold of the action of T on the sexuality, if any, would be at supra-physiological levels.
Androgenotherapy of sexual dysfonctionnalities is wittnissing a constant evolution. New and more performing products, as well as novel and less astreignant ways of administration, are already disponible or under evaluation. Moreover, the improvement of plasmic androgen exploration (dosage of free and non-sex hormone-binding globulin bound testosterone) associated to a better understanding of side effects of the androgenic therapeutics may allow in the near futur to reach a consensus on the androgenotherapy indications. As a matter of fact among the population of patients considered eugonadic (based on normal levels of T) and showing a sexual dysfonctionality, two subgroups might be interested: That of elderly patients displaying either an increase of the hormone-binding globulin (SHBG) or a decrease of the non-sex hormone-binding globulin bound testosterone levels and that of young patients suffering from idiopathic impotence. It should be, however, pointed at that the recent character of the different physiopathologic and therapeutic acquisitions requires a validation through larger series and long term studies.
References
ANDERSON R., BANCROFT J., WU F.: The effects of exogenous testosterone one sexuality in normal men. J. Clin. Endocrinol. Metab. 1992, 75: 1503–1507.
ARON C.: La Neurobiologie du Comportement Sexuel des Mammifères. ed Hermann. Paris, 1984, VIII: 57–107
BALS-PRATSCH M., KNUTH U.A., YOON Y.D., NIESCHLAG E.: Transdermal Testosterone substitution Therapy for Male Hypogonadism. The Lancet, 1986, 25: 943–946.
BANCROFT J.: Endocrinology of sexual fonction. Clin. Obstet. Gynecol. 1980, 7: 253–281
BANCROFT J.: Hormones and human sexual behavior. J. Sex. Marital Ther. 1984, 10: 3–21.
BANCROFT J.: Sexual desire and the brain. Sex. Marit. Ther. 1988, 3: 11–27.
BARDIN C. WAYNE., SWERDLOFF R.S., SANTEN R.J.: Androgens: Risks and Benefits. J. Clin. Endocrinol. Metab. 1991, 73, 1: 4–7.
BEHRE H.M., NIECHLAG E.: Testosterone Buciclate (20 A et 1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Longacting Androgen Ester. J. Clin. Endocrinol. Metab. 1992, 75, 5: 1204–1210.
BHASIN S., SWERDLOFF RS., STEINER B., et al.: A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. 1992, 74: 75–83.
BONNET P., REITER E., BRUYNINX M.: Benign Prostatic Hyperplasia and Normal Prostate Aging: Differences in Types I and II 5α-Reductase and Steroid Hormone Receptor Messenger Ribonucleic Acid (mRNA) Levels, but not in Insuli-Like Growth Factor mRNA Levels. J. Clin. Endocrinol. Metab. 1993, 77, 5: 1203–1208.
BOUDON CH, TERRAZA A., NAVARRO M., et al.: Activité 5α-réductase des cellules de prostate humaine en culture. Andrologie, 1993, 3, 1: 50.
BURRIS A.S., EWING L.L., SHERINS R.J.: Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil. steril. 1988, 50: 493–497.
BUVAT J., BUVAT-HERBAUT M., LEMAIRE A., MARCOLIN G.: Hormone, Neurotransmetteurs Centraux et Comportement Sexuel de l'Homme. In: Arvis G, ed. Andrologie, tome III, Paris: Maloine, 1991: 1661–1689
BUVAT J.: Neurotransmetteurs cérébraux et contrôle du comportement sexuel masculin. Andrologie, 1996, 6, 2: 184–199.
CARANI C., BANCROFT J., GRANATA A., DEL RIO G., MARRAMA P.: Testosterone and Erectile Function, Nocturnal Penile Tumescence and Rigidity, and Erectile Reponse to Visual Erotic Stimuli in Hypogonadal and eugonadal Men. Psychoneuroendocrinology, 1992, 17, 6: 647–654.
CARRIE J. BAGATELL., HERMEN JR., RIVIER JE., BREMNER W.J.: Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men. J. clin. Endocrinol. Metab. 1994, 78, 3, 711–716.
CARRIE J. BAGATELL., HERMEN J.R., MATSUMOTO A.M., RIVIER J.E., BREMNER W.J.: Metabolic and behavioral effects of high-dose exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 1994, 79, 2: 561–567.
DEVIGNES D., MAHMOUD W., GUECHOT J., ARVIS G., GIBOUDEAU J.: Intérêt du dosage de la testostérone biodisponible dans les dysérections. Andrologie, 1996, 6, 2: 200–207.
GOOREN L.J.C.: Human male sexual functions do not require aromatisation of testosterone: a study using tamoxifen, testolactone and dihydrotestostérone: Arch. sex. behav, 1985, 14: 539–548.
GRIFFING G.T.: Editorial: Dinosaurs and steroids. J. Clin. Endocrinol. Metab., 1993, 77, 6: 1450–1451.
HAFFNER S.M., MYKKANEN L., VALDEZ R.A., KATZ M.S.: Relationship of Sex Hormones to Lipids and Lipoproteins in Non diabetic Men. J. Clin. Endocrinol. Metab., 1993, 77, 6: 1610–1615
HANDELSMAN D.J., CONWAY A.J., BOYLAN L.M.: Pharmacokinetics and pharmacodynamics of testosterone pellets in men. J. Clin. Endocrinol. Metab., 1990, 70: 216–221.
HEATON J.P.W., SCHWAN J. VARRIN: Effects of Castration and Exogenous Testosterone Supplementation in an Animal Model of Penile Erection. J. Urol, 1994, 151: 797–800.
HOLMANG A., SVEDBERG J., JENNISCHE E., BJORNTORP P.: The effects of testosterone on muscle insulin-sensitivity and morphology in female rats. Am. J. physiol, 1990, 259: E 555-E 560.
HOLMANG A., BJORNTORP P.: The effects of testosterone on insulin sensitivity in male rats. Acta Physiol. Scand., 1992, 140: 505–510.
HOOP R.C., PLYMATE S.R.: Regulation of sex hormone binding globulin gene expression by steroid and peptides hormones. Proc. of the 8th int. Congr of hormonal steroids. 1990.
KWAN M., GREENLEAF WJ., MANN J., CRAPO L., DAVIDSON J.M.: The nature of androgen action on male sexuality: combined laboratoryself-report study on hypogonadal men. J. Clin. Endocrinol. Metab., 1983, 57: 557–562.
LEJEUNE H., DECHAUD H.: Dosage de la testostérone plasmatique chez l'homme. Andrologie, 1994, 4, 2: 216–222.
LIU XIN-HUA, STEVEN WILEY H., WAYNE MEIKLE A.: Androgens Regulate Proliferation of Human Prostate Cancer Cells in Culture by Increasing Transforming Growth Factor-a (TGF-α) and Epidermal Growth Factor (EGF)/TGF-α Receptor. J. Clin. Endocrinol. Metab., 1993, 77, 6: 1472–1478.
LUISI M., FRANCHI R.: Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J. endocrinol. invest., 1980, 3: 305–308.
MATSUMOTO A.M.: “Andropause” Are reduced Androgen Levels in Aging Men Physiogically Important? WJM, 1993, 159, 5: 618–620.
McCONNELL J., BARTSCH G., DEBRUYNE F., LE DUC A., MAHLER C. PAVONE-MACALUSO M. et al: Hormonal treatment of benign prostatic hyperplasia: Proc. of the international consultation on benign prostatic hyperplasia (BHP). Paris, 1991, 179–191.
McCONNELL J.D., WILSON J.D., GEORGE F.W., GELLER J., PAPPAS F., STONER E.: Finasteride, an Inhibitor of 5α-Reductase, Suppresses Prostatic Dihydrotestosterone in Men with Benign Prostatic Hyperplasia. J. Clin. Endocrinol. Metab., 1992, 74, 3: 505–508.
MOSS H.B., PANZAK G.L., TARTER R.E.: Sexual Functioning of Male Anabolic Steroid Abusers. Arch Sex Behav., 1993, 22, 1: 1–12.
MOWSZOWICZ I., BERTHAUT I., MESTAYER CH., WRIGHT F., KUTTENN F., MAUVAIS-JARVIS P.: 5α-Reductases: Physiologie et Pathologie. Andrologie 1994, 4, 1: 71–77.
NIECHLAG E., BEHRE HM.: Comparative pharmacokinetics of testosterone preparations: application of computer analysis and simulation. In: NIECHLAG E., BEHRE HM., eds. Testosteroneaction, deficiency, substitution, Berlin: Heidelberg, New york: Springer-Verlag: 115–35.
O'CARROLL R., BANCROFT J.: Testosterone therapy for low sexual interest and erectile dysfunction in men: A controlled study. 1984, Br. J. psychiat, 145: 146–151.
PASQUALI R., CASIMIRRI F., CANTABELLI S., et al.: Effects of obesity and body fat distribution on sex hormones and insulin in men: Metabolism, 40: 101–104.
PHILLIPS G.: Relationships between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism. 1993, 42: 116–120.
RAFEEQ A.S., BOUCHER A.E., MANNI A., SANTEN R.J., BARTHOLOMEW M., DEMERS L.M.: Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism. J. Clin. endocrinol. Metab., 1988, 66, 3: 546–551.
ROBEL P.: Recepteur et Mécanismes d'Action des Androgènes. Andrologie, 1993, 3, 4: 51–57.
ROBEL P., GIULLIANO F., RAMPIN O.: Risques potentiels des inhibiteurs de la 5a-reductase pour le comportement sexuel masculin. Andrologie, 1995, 5, 2: 230–235.
SALMINIES S., KOCKOTT G., PIRKE KM., VOGT HJ., SCHILL WB.: Effects of testosterone remplacement on sexual behavior in hypogonadal men. Arch. Sex. Behav., 1982, 11: 345–353.
SIMPKINS J.W., KALRA P.S., KALRA S.P.: Variable effects of testosteron on dopamin activity in several microdissected regions in the preoptic ares and medial basal hypothalamus. endocrinology, 1983, 112: 665.
SMITH E.P., BOYD J., FRANK G.R. et al.: Estrogen resistance caused by a mutation in the estrogen-receptor gene in man. New Engl. J. Med., 1994, 331: 1056–1061.
STEFANICK M.L., WILLIAMS P.T., KRAUSS R.M., TERRY R.B., VRANIZAN K.M., WOOD P.D.: Relationships of plasma estradiol, testostérone, and sex hormone-binding globuline with lipoproteine, apolipoproteine and high density lipoproteine subfractions in men. J. clin. Endocrinol. Metab., 1987, 64: 723–729.
VITTO G.A., KAUFMAN J.M., VERMEULEN A.: Pathogenis of the decreased androgen levels in obese men. J. clin. Endocrinol. Metab., 1994, 79, 4: 997.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hafidi, A., Gharbi, M.H. Androgènes et sexualité masculine. Androl. 6 (Suppl 4), 387–397 (1996). https://doi.org/10.1007/BF03034459
Issue Date:
DOI: https://doi.org/10.1007/BF03034459